Background: Diabetic nephropathy (DN) is a common complication of diabetes mellitus (DM) and also a major cause of end-stage renal disease (ESRD). Olmesartan medoxomil (OM) is an angiotensin II receptor blocker (ARB) and has been shown to exhibit renoprotective effects on a streptozotocin (STZ)-induced diabetic rat model. Yet, whether OM affects DN progression and renal injury in db/db mice, a type 2 diabetic murine model, has not been established. Methods: Wild-type (n = 15) and db/db mice (n = 15) were treated with control saline or OM via oral gavage. The physiological and biochemical parameters were evaluated and histological examinations of kidney specimens were performed. Results: Compared with saline-treated db/db mice, db/db mice administered with OM showed ameliorated diabetic physiological and biochemical parameters. In addition, OM decreased urinary albumin excretion and plasma creatinine level in db/db mice. Moreover, histologically, OM reduced glomerular hypertrophy and injury, and also ameliorated tubular injury, thus suggesting that OM improves renal function and minimizes renal pathological deterioration in db/db mice. Conclusion: Our study reveals a beneficial role of OM in ameliorating DN in db/db mice, which is associated with its renoprotective function.
CITATION STYLE
Zhu, Y., Li, Z. L., Ding, A., Yang, H., Zhu, W. P., Cui, T. X., … Zhang, H. (2019). Olmesartan medoxomil, an angiotensin ii-receptor blocker, ameliorates renal injury in db/db mice. Drug Design, Development and Therapy, 13, 3657–3667. https://doi.org/10.2147/DDDT.S217826
Mendeley helps you to discover research relevant for your work.